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INTRODUCTION 
Currently, severe acute respiratory syndrome coronavirus 
2 (SARS-CoV-2), which causes coronavirus disease 2019 
(COVID-19), is spreading globally (1, 2), and the World Health 
Organization (WHO) has declared it a pandemic. As of June 
2, 2020, more than 6.1 million confirmed cases and more than 
376,000 deaths have been reported worldwide (3). 
SARS-CoV-2 infection usually results in a mild disease 
course with spontaneous resolution in the majority of in-
fected individuals (4). However, some patients, particularly 
elderly patients develop severe COVID-19 infection that re-
quires intensive care with mechanical ventilation (4, 5). The 
mortality rate for COVID-19 in Wuhan, China, is estimated to 
be 1.4% (5). Although this rate is lower than that of severe 
acute respiratory syndrome (SARS) and Middle East respira-
tory syndrome (MERS), which are caused by other human 
pathogenic coronaviruses (6), it is much higher than that of 
influenza, a common respiratory viral disease requiring hos-
pitalization and intensive care in severe cases. 
In severe cases of COVID-19, a hyper-inflammatory re-
sponse, also called a cytokine storm, has been observed and 
is suspected of causing the detrimental progression of 
COVID-19 (7). Circulating levels of pro-inflammatory cyto-
kines, including TNF and IL-6, are increased in severe cases 
(8). Gene expression analyses have also shown that IL-1-
related pro-inflammatory pathways are highly up-regulated 
in severe cases (9). In a murine model of SARS-CoV infection, 
a delayed, but considerable type I IFN (IFN-I) response 
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Although most SARS-CoV-2-infected individuals experience mild coronavirus disease 2019 (COVID-19), 
some patients suffer from severe COVID-19, which is accompanied by acute respiratory distress syndrome 
and systemic inflammation. To identify factors driving severe progression of COVID-19, we performed 
single-cell RNA-seq using peripheral blood mononuclear cells (PBMCs) obtained from healthy donors, 
patients with mild or severe COVID-19, and patients with severe influenza. Patients with COVID-19 exhibited 
hyper-inflammatory signatures across all types of cells among PBMCs, particularly up-regulation of the 
TNF/IL-1β-driven inflammatory response as compared to severe influenza. In classical monocytes from 
patients with severe COVID-19, type I IFN response co-existed with the TNF/IL-1β-driven inflammation, and 
this was not seen in patients with milder COVID-19. Interestingly, we documented type I IFN-driven 
inflammatory features in patients with severe influenza as well. Based on this, we propose that the type I 
IFN response plays a pivotal role in exacerbating inflammation in severe COVID-19. 
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promotes the accumulation of monocytes-macrophages and 
the production of pro-inflammatory cytokines, resulting in le-
thal pneumonia with vascular leakage and impaired virus-
specific T-cell responses (10). 
Immune dysfunction is also observed in patients with 
COVID-19. In severe cases, the absolute number of T cells is 
reduced (8, 11), and the T cells exhibit functional exhaustion 
with the expression of inhibitory receptors (12, 13). However, 
hyper-activation of T cells as reflected in the up-regulation of 
CD38, HLA-DR, and cytotoxic molecules was also reported in 
a lethal case of COVID-19 (14). Immune dysfunction in pa-
tients with severe COVID-19 has been attributed to pro-in-
flammatory cytokines (15). 
In the present study, we performed single-cell RNA-seq 
(scRNA-seq) using peripheral blood mononuclear cells 
(PBMCs) to identify factors associated with the development 
of severe COVID-19 infection. By comparing COVID-19 and 
severe influenza, we report that the TNF/IL-1β-driven inflam-
matory response was dominant in COVID-19 across all types 
of cells among PBMCs, whereas the up-regulation of various 
interferon-stimulated genes (ISGs) was prominent in severe 
influenza. When we compared the immune responses from 
patients with mild and severe COVID-19 infections, we found 
that classical monocytes from severe COVID-19 exhibit IFN-




Single-cell transcriptomes of PBMCs from patients with 
COVID-19 and influenza 
PBMCs were collected from healthy donors (n=4), hospi-
talized patients with severe influenza (n=5), and patients 
with COVID-19 of varying clinical severity, including severe, 
mild, and asymptomatic (n=8). PBMCs were obtained twice 
from three (the subject C3, C6, and C7) of the eight COVID-19 
patients at different time points during hospitalization. 
PBMC specimens from COVID-19 patients were assigned to 
severe or mild COVID-19 groups according to the National 
Early Warning Score (NEWS; mild < 5, severe ≥ 5) evaluated 
on the day of whole blood sampling (16). In NEWS scoring, 
respiratory rate, oxygen saturation, oxygen supplement, body 
temperature, systolic blood pressure, heart rate, and con-
sciousness were evaluated (16). Severe influenza was defined 
when hospitalization was required irrespective of NEWS 
score. Patients with severe influenza were enrolled from De-
cember 2015 to April 2016, prior to the emergence of COVID-
19. The severe COVID-19 group was characterized by signifi-
cantly lower lymphocyte count and higher serum level of C-
reactive protein than the mild COVID-19 group on the day of 
blood sampling (Fig. S1A). Multiplex real-time PCR for N, 
RdRP, and E genes of SARS-CoV-2 was performed, and there 
was no statistical difference in Ct values for all three genes 
between two groups (Fig. S1B). Demographic information is 
provided with experimental batch of scRNA-seq in Table S1 
and clinical data in Table S2 and S3. 
Employing the 10X Genomics scRNA-seq platform, we an-
alyzed a total of 59,572 cells in all patients after filtering the 
data with stringent high quality, yielding a mean of 6,900 
UMIs per cell and detecting 1,900 genes per cell on average 
(Table S4). The transcriptome profiles of biological replicates 
(PBMC specimens in the same group) were highly reproduci-
ble (Fig. S1C), ensuring the high quality of the scRNA-seq data 
generated in this study. 
To examine the host immune responses in a cell type-spe-
cific manner, we subjected 59,572 cells to t-distributed sto-
chastic neighbor embedding (tSNE) based on highly variable 
genes using the Seurat package (17) and identified 22 differ-
ent clusters unbiased by patients or experimental batches of 
scRNA-seq (Fig. 1A, Fig. S1D). These clusters were assigned to 
13 different cell types based on well-known marker genes and 
two uncategorized clusters (Fig. 1B and C, and Table S5). In 
downstream analysis, we only focused on 11 different im-
mune cell types, including IgG- B cell, IgG+ B cell, effector 
memory (EM)-like CD4+ T cell, non-EM-like CD4+ T cell, EM-
like CD8+ T cell, non-EM-like CD8+ T cell, natural killer (NK) 
cell, classical monocyte, intermediate monocyte, non-classi-
cal monocyte, and dendritic cell (DC) after excluding plate-
lets, red blood cells (RBCs), and two uncategorized clusters. 
The subject C8 (asymptomatic case) was also excluded due to 
a lack of replicates. In hierarchical clustering, most transcrip-
tome profiles from the same cell type tended to cluster to-
gether, followed by disease groups, suggesting that both 
immune cell type and disease biology, rather than technical 
artifacts, are the main drivers of the variable immune tran-
scriptome (Fig. S1E). 
As a feature of immunological changes, we investigated 
the relative proportions of immune cells among PBMCs in the 
disease groups compared to the healthy donor group (Fig. 1D 
and E, and Fig. S1F). Unlike the limited changes in mild 
COVID-19, significant changes were observed in both influ-
enza and severe COVID-19 across multiple cell types among 
PBMCs. In severe COVID-19, the proportion of classical mon-
ocytes significantly increased whereas those of DCs, non-clas-
sical monocytes, intermediate monocytes, NK cells, EM-like 
CD8+ T cells, and EM-like CD4+ T cells significantly decreased 
(Fig. 1E). In severe influenza, the proportion of classical mon-
ocytes significantly increased whereas those of DCs, non-EM-
like CD4+ T cells, EM-like CD4+ T cells, IgG+ B cells, and IgG- 
B cells significantly decreased. We validated the proportions 
of immune cell subsets from scRNA-seq by flow cytometry 
analysis. The relative proportions of total lymphocytes, B 
cells, CD4+ T cells, CD8+ T cells, NK cells, and total monocytes 
from scRNA-seq significantly correlated with those from flow 
cytometry analysis (Fig. S1G). 
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Transcriptional signatures associated with COVID-19 
In order to compare the effect of infection between dis-
eases, we performed hierarchical clustering based on relative 
gene expression changes against the healthy donor group. 
Unexpectedly, all types of cells among PBMCs were clustered 
together according to the disease groups instead of cell-types 
(Fig. 2A). Further investigation of the variable genes based on 
K-means clustering supported COVID-19-specific up- or 
down-regulated gene expression patterns across all types of 
cells among PBMCs (Fig. S2A). These results indicate that, in 
COVID-19, peripheral blood immune cells may be influenced 
by common inflammatory mediators regardless of cell type. 
Despite distinct transcriptional signatures between COVID-
19 and influenza, severe COVID-19 and influenza shared tran-
scriptional signatures in all types of monocytes and DCs 
(black boxed region in Fig. 2A), possibly reflecting common 
mechanisms underlying the innate immune responses in se-
vere influenza and severe COVID-19. 
Next, we sought to identify relevant biological functions 
in disease-specific up- or down-regulated genes in terms of 
the GO biological pathways. First, we combined both mild 
and severe COVID-19 as a COVID-19 group and identified dis-
ease-specific changes in genes for each cell type compared to 
the healthy donor group using model-based analysis of single 
cell transcriptomics (MAST) (18). NFKB1, NFKB2, IRF1, and 
CXCR3 were specifically up-regulated in COVID-19, and 
CXCL10, STAT1, TLR4, and genes for class II HLA and im-
munoproteasome subunits were specifically up-regulated in 
influenza (Table S6). TNF, TGFB1, IL1B, and IFNG were com-
monly up-regulated. When we directly compared COVID-19 
and influenza, NFKB1, NFKB2, and TNF were up-regulated in 
COVID-19, whereas STAT1, TLR4, and genes for immunopro-
teasome subunits were up-regulated in influenza. For each 
group of differentially expressed genes (DEGs), we identified 
the top 10 enriched GO biological pathways and collected 
them to demonstrate p-value enrichment in each group of 
DEGs (Fig. 2B). Both distinct and common biological func-
tions were identified as illustrated by inflammatory response 
genes being highly active in both COVID-19 and influenza, 
but genes for transcription factors, including inflammatory 
factors (i.e., NFKB1/2, and STAT4) were up-regulated in 
COVID-19. In contrast, a limited response in genes associated 
with the IFN-I and -II signaling pathways, T-cell receptor 
pathways, and adaptive immune response was observed in 
COVID-19 compared to influenza. Such disease-specific gene 
expression patterns were exemplified at single cell resolution 
by GBP1 (IFN-γ-mediated signaling pathway) being specifi-
cally up-regulated in influenza, CREM (positive regulation of 
transcription) being specifically up-regulated in COVID-19, 
and CCL3 (inflammatory response) being commonly up-reg-
ulated (Fig. 2C and Table S7). 
We expanded our analysis in a cell type specific manner 
by conducting weighted gene correlation network analysis 
(WGCNA) (19) for the collected genes associated with Fig. 2B. 
We identified several modular expression patterns (Fig. 2D 
and Table S8). In the COVID-19 group, NFKB1/2, JUN, and 
TNF were modularized in CD8+ T and NK cells (G6 and G7 in 
Fig. 2D), and IL1B, NFKBID, and OSM were modularized in 
all types of monocytes and DCs (G3 in Fig. 2D). In the influ-
enza group, GBP1, TAP1, STAT1, IFITM3, OAS1, IRF3, and 
IFNG were modularized in all types of T cells and NK cells 
(G2 in Fig. 2D), and CXCL10 and TLR4 were modularized in 
all types of monocytes and DCs (G5 and part of G6 in Fig. 2D). 
Consistently, the DEGs between COVID-19 and influenza 
were dominant in CD8+ T cells and all types of monocytes 
(Fig. S2B). 
Distinct subpopulations of CD8+ T cells in COVID-19 
and influenza 
To uncover disease-specific transcriptional signatures in 
CD8+ T cells, we performed sub-clustering analysis from EM-
like and non-EM-like CD8+ T cell clusters using Seurat (17). 
Each disease group-specifically enriched sub-clusters com-
pared to the two other groups were identified in the non-EM-
like CD8+ T cell cluster (Fig. 3A). Of the six sub-clusters from 
the non-EM-like CD8+ T cell cluster, cluster 1 and cluster 3 
were significantly enriched in the influenza and COVID-19 
groups, respectively (Fig. 3B and C, and S3A). Clusters with 
the high expression of PPBP, a marker of platelets, were ex-
cluded in following analysis (e.g., cluster 6 in Fig. S3A). Intri-
guingly, up-regulated genes in cluster 1 and cluster 3 were 
associated with previously defined gene sets for ‘influenza A 
virus infection’ and ‘SARS-CoV infection’, respectively (Fig. 
S3B) (20). We also found that the cluster 3-specific up-regu-
lated genes reflect activation of immune response, including 
CD27, RGS1, CCL5, SELL, and RGS10 (Fig. S3C and Table S9). 
Protein interaction network analysis of selected top 30 up-
regulated genes in each cluster based on STRING v11 (21) re-
vealed the up-regulation of PRF1, GNLY, GZMB, and GZMH 
in cluster 1 and the up-regulation of GZMK, GZMA, CXCR3, 
and CCL5 in cluster 3 (Fig. 3D, green). STAT1, TAP1, PSMB9, 
and PSME2, which are up-regulated preferentially by IFN-γ, 
were overexpressed only in influenza-specific cluster 1 (Fig. 
3D, blue). We validated these data by intracellular staining 
for granzyme B and PMA/ionomycin-stimulated intracellular 
cytokine staining for IFN-γ. The percentages of granzyme B+ 
and IFN-γ+ cells among CD8+ T cells were significantly higher 
in the influenza group than in the COVID-19 group (Fig. S3D). 
Of the seven representative GO biological pathways for the 
pro-inflammatory and IFN responses, pathways for responses 
to IFN-I and -II were more associated with influenza-specific 
cluster 1, whereas pathways for the response to TNF or IL-1β 
were more prominent in COVID-19-specific cluster 3 (Fig. 
3E). 
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Transcriptional signatures of classical monocytes in 
COVID-19 
We performed sub-clustering analysis from all three types 
of monocyte clusters to find COVID-19-specific sub-clusters. 
However, there was no COVID-19-specifically enriched sub-
cluster (Fig. S4A and B). Next, we further focused on classical 
monocytes considering their crucial roles for inflammatory 
responses. We investigated DEGs between influenza and 
COVID-19 to seek COVID-19-specific transcriptional signa-
tures in classical monocytes (Fig. 4A). Interestingly, TNF and 
IL1B, major genes in the inflammatory response, were identi-
fied as COVID-19-specific and commonly up-regulated genes, 
respectively. To better characterize the transcriptional signa-
tures in classical monocytes, we performed K-means cluster-
ing of up-regulated genes in at least one disease group 
compared to the healthy donor group. We identified five dif-
ferent clusters of up-regulation (Fig. 4B and Table S10): genes 
in cluster 1 are commonly up-regulated in all disease groups, 
cluster 2 is influenza-specific, cluster 3 is associated with 
mild/severe COVID-19, cluster 4 is associated with influenza 
and severe COVID-19, and cluster 5 is severe COVID-19-
specific. 
We examined each cluster-specific genes by gene set en-
richment analysis (GSEA) using cytokine-responsive gene 
sets originated from each cytokine-treated cells (LINCS 
L1000 ligand perturbation analysis in Enrichr) (22). COVID-
19-specific cluster 3 genes were enriched by TNF/IL-1β-
responsive genes whereas influenza-specific cluster 2 genes 
were enriched by IFN-I-responsive genes in addition to 
TNF/IL-1β-responsive genes (Fig. 4C), indicating that the 
IFN-I response is dominant in influenza compared to COVID-
19. We confirmed this result by analyzing cluster-specific 
genes with cytokine-responsive gene sets originated from 
other sources (Fig. 4D). Unexpectedly, cluster 4 and 5 exhib-
ited strong associations with IFN-I-responsive genes, in addi-
tion to TNF/IL-1β-responsive genes (Fig. 4E), indicating that 
severe COVID-19 acquires IFN-I-responsive features in addi-
tion to TNF/IL-1β-inflammatory features. 
IFN-I response in addition to TNF/IL-1β inflammatory 
response in severe COVID-19 
Next, we directly compared classical monocytes between 
mild and severe COVID-19. When we analyzed DEGs, severe 
COVID-19 was characterized by up-regulation of various 
ISGs, including ISG15, IFITM1/2/3, and ISG20 (Fig. 5A). Both 
TNF/IL-1β-responsive genes and IFN-I-responsive genes 
were enriched in severe COVID-19-specific up-regulated 
genes (Fig. 5B). We measured plasma concentrations of TNF, 
IL-1β, IL-6, IFN-β, IFN-γ, and IL-18 in a larger cohort of 
COVID-19 patients. Among these cytokines, IL-6 and IL-18 
were significantly increased in severe COVID-19 compared to 
mild COVID-19 whereas there was no difference in plasma 
concentrations of the other cytokines between the two groups 
(Fig. S5A). These results indicate that cytokine-responsive 
gene signatures cannot be simply explained by a few cyto-
kines because of overlapped effects of cytokines. 
To further investigate the characteristics of severe COVID-
19, we performed a trajectory analysis with Monocle 2 (23) 
using two internally well-controlled specimens (one severe 
and one mild) in which both PBMC samples were collected 
from a single patient (the subject C7) with COVID-19. Trajec-
tory analysis aligned classical monocytes along the disease 
severity with cluster 1 and cluster 3 corresponding to later 
and earlier Pseudotime, respectively (Fig. 5C). Representative 
genes in cluster 1 was enriched in the severe stage and highly 
associated with the both IFN-I and TNF/IL-1β-associated in-
flammatory response (Fig. 5D, Fig. S5B, and Table S11). GSEA 
confirmed that both the IFN-I response and TNF/IL-1β in-
flammatory response were prominent in cluster 1, but not in 
cluster 3 (Fig. 5E). Cluster 1 exhibited a significantly higher 
association with a gene set from systemic lupus erythemato-
sus, which is a representative inflammatory disease with IFN-
I features, than cluster 3 (Fig. 5F, left), but was not signifi-
cantly associated with a gene set from rheumatoid arthritis 
(Fig. 5F, right). 
We obtained additional evidence of the IFN-I-potentiated 
TNF inflammatory response in severe COVID-19 by analyzing 
a gene module that is not responsive to IFN-I, but associated 
with TNF-induced tolerance to TLR stimulation. Park et al. 
previously demonstrated that TNF tolerizes TLR-induced 
gene expression in monocytes, though TNF itself is an inflam-
matory cytokine (24). They also showed that IFN-I induces a 
hyper-inflammatory response by abolishing the tolerance ef-
fects of TNF, and defined a gene module responsible for the 
IFN-I-potentiated TNF-NF-κB inflammatory response as 
‘class 1’ (24). This gene module was significantly enriched in 
cluster 1, but not in cluster 3 (Fig. 5G), which suggests that 
the IFN-I response may exacerbate hyper-inflammation by 
abolishing a negative feedback mechanism. 
Validation of hyperinflammatory features combined 
with IFN-I response in lung tissues from a lethal case of 
COVID-19 
Finally, we validated IFN-I response and inflammatory 
features using bulk RNA-seq data obtained using post-mor-
tem lung tissues from patients with lethal COVID-19 (25). Alt-
hough the analysis was limited to only two patients without 
individual cell-type resolution, in genome browser, up-regu-
lation of IFITM1, ISG15, and JAK3 and down-regulation of 
RPS18 were observed commonly in post-mortem COVID-19 
lung tissues and classical monocytes of severe COVID-19 (Fig. 
6A). In the analysis with cytokine-responsive gene sets, both 
the IFN-I response and TNF/IL-1β-inflammatory response 
were prominent in the lung tissues (Fig. 6B). DEGs in the 
lung tissues were significantly associated with cluster 4, 
which is commonly up-regulated in both influenza and severe 
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COVID-19, and cluster 5, which is specific to severe COVID-
19 in Fig. 4B (Fig. 6C). These genes were also significantly 
associated with the cluster 1 identified in the trajectory anal-
ysis, but not with cluster 3 (Fig. 6D). When gene sets were 
defined by DEGs between mild and severe COVID-19, the 
DEGs in post-mortem lung tissues were significantly associ-




Severe COVID-19 has been shown to be caused by a hyper-
inflammatory response (7). Particularly, inflammatory cyto-
kines secreted by classical monocytes and macrophages are 
considered to play a crucial role in severe progression of 
COVID-19 (26). In the current study, we confirmed the results 
from previous studies by showing that the TNF/IL-1β inflam-
matory response is dominant in COVID-19 although a small 
number of patients were enrolled. However, we also found 
that severe COVID-19 is accompanied by the IFN-I response 
in addition to the TNF/IL-1β response. These results indicate 
that the IFN-I response might contribute to the hyper-inflam-
matory response by potentiating TNF/IL-1β-driven inflam-
mation in severe progression of COVID-19. 
In the current study, we carried out scRNA-seq using 
PBMCs instead of specimens from the site of infection, e.g., 
lung tissues or bronchoalveolar lavage (BAL) fluids. However, 
hierarchical clustering based on relative changes to the 
healthy donor group showed that all types of cells among 
PBMCs were clustered together according to the disease 
groups as shown in Fig. 2A, indicating that there is disease-
specific global impact across all types of cells among PBMCs. 
This finding suggests that peripheral blood immune cells are 
influenced by common inflammatory mediators regardless of 
cell type. However, we could not examine granulocytes in the 
current study because we used PBMCs, not whole blood sam-
ples for scRNA-seq. 
In transcriptome studies for cytokine responses, we often 
analyze cytokine-responsive genes rather than cytokine genes 
themselves. However, we cannot exactly specify responsible 
cytokine(s) from the list of up-regulated genes because of 
overlapped effects of cytokines. For example, up-regulation of 
NF-κB-regulated genes can be driven by TNF, IL-1β or other 
cytokines, and up-regulation of IFN-responsive genes can be 
driven by IFN-I or other interferons. In the current study, we 
designated the IFN-I response because many up-regulated 
IFN-responsive genes were typical ISGs. 
Recently, Wilk et al. also performed scRNA-seq using 
PBMCs from COVID-19 patients and healthy controls (27). 
Similar to our study, they found IFN-I-driven inflammatory 
signatures in monocytes from COVID-19 patients. However, 
they did not find substantial expression of pro-inflammatory 
cytokine genes such as TNF, IL6, IL1B, CCL3, CCL4 and 
CXCL2 in peripheral monocytes from COVID-19 patients 
whereas we detected the up-regulation of TNF, IL1B, CCL3, 
CCL4 and CXCL2 in the current study. Moreover, they found 
a developing neutrophil population in COVID-19 patients 
that was not detected in our study. These discrepant results 
might be due to different platforms for scRNA-seq. Wilk et al. 
used the Seq-Well platform whereas we used the 10X Ge-
nomics platform that is more generally used. We also note 
that recent scRNA-seq analyses of COVID-19 sometimes lead 
to unrelated or contradictory conclusions to each other de-
spite the same platform (28, 29). Although it often occurs in 
unsupervised analysis of highly multi-dimensional data, 
more caution will be required in designing scRNA-seq analy-
sis of COVID-19, including definition of the severity and sam-
pling time points. 
Recently, Blanco-Melo et al. examined the transcriptional 
response to SARS-CoV-2 in in vitro infected cells, infected fer-
rets, and post-mortem lung samples from lethal COVID-19 
patients and reported that IFN-I and -III responses are atten-
uated (25). However, we noted that IFN-I signaling pathway 
and innate immune response genes were relatively up-regu-
lated in post-mortem lung samples from lethal COVID-19 pa-
tients compared to SARS-CoV-2-infected ferrets in their 
paper. Given that SARS-CoV-2 induces only mild disease 
without severe progression in ferrets (30), we interpret that 
IFN-I response is up-regulated in severe COVID-19 (e.g., post-
mortem lung samples from lethal COVID-19 patients), but 
not in mild COVID-19 (e.g., SARS-CoV-2-infected ferrets). In-
deed, severe COVID-19-specific signatures discovered in our 
current study were significantly enriched in the publically 
available data of post mortem lung tissues from the Blanco-
Melo et al.’s study although the analysis was limited to only 
two patients without individual cell-type resolution (Fig. 6). 
In a recent study, Zhou et al. also found a robust IFN-I re-
sponse in addition to pro-inflammatory response in BAL fluid 
of COVID-19 patients (31). Moreover, up-regulation of IFN-I-
responsive genes has been demonstrated in SARS-CoV-2-
infected intestinal organoids (32). 
Although IFN-I has direct antiviral activity, their im-
munopathological role was also reported previously (33). In 
particular, the detrimental role of the IFN-I response was el-
egantly demonstrated in a murine model of SARS (10). In 
SARS-CoV-infected BALB/c mice, the IFN-I response induced 
the accumulation of pathogenic inflammatory monocytes-
macrophages and vascular leakage, leading to death. It was 
proposed that a delayed, but considerable IFN-I response is 
critical for the development of acute respiratory distress syn-
drome and increased lethality during pathogenic coronavirus 
infection (6, 34). 
Currently, the management of patients with severe 
COVID-19 relies on intensive care and mechanical ventilation 
without a specific treatment because the pathogenic 
First release: 10 July 2020  immunology.sciencemag.org  (Page numbers not final at time of first release) 6 
 
mechanisms of severe COVID-19 have not yet been clearly 
elucidated. In the current study, we demonstrated that severe 
COVID-19 is characterized by TNF/IL-1β-inflammatory fea-
tures combined with the IFN-I response. In a murine model 
of SARS-CoV infection, timing of the IFN-I response is a crit-
ical factor determining outcomes of infection (6, 10). Delayed 
IFN-I response contributes to pathological inflammation 
whereas early IFN-I response controls viral replication. 
Therefore, we propose that anti-inflammatory strategies tar-
geting not only inflammatory cytokines, including TNF, IL-
1β, and IL-6, but also pathological IFN-I response needs to be 
investigated for the treatment of patients with severe COVID-
19. 
 
MATERIALS AND METHODS 
Patients 
Patients diagnosed with COVID-19 were enrolled from 
Asan Medical Center, Severance Hospital, and Chungbuk Na-
tional University Hospital. SARS-CoV-2 RNA was detected in 
patients’ nasopharyngeal swab and sputum specimens by 
multiplex real-time reverse-transcriptase PCR using the All-
plex 2019-nCoV Assay kit (Seegene, Seoul, Republic of Korea). 
In this assay, N, RdRP, and E genes of SARS-CoV-2 were am-
plified, and Ct values were obtained for each gene. SARS-CoV-
2-specific antibodies were examined using the SARS-CoV-2 
Neutralization Antibody Detection kit (GenScript, Pisca-
taway, NJ) and were positive in all COVID-19 patients in con-
valescent plasma samples or the last plasma sample in a 
lethal case. Hospitalized patients diagnosed with influenza A 
virus infection by a rapid antigen test of a nasopharyngeal 
swab were also enrolled from Asan Medical Center and 
Chungbuk National University Hospital from December 2015 
to April 2016, prior to the emergence of COVID-19. Patients’ 
clinical features, laboratory findings, and chest radiographs 
were collected from their electronic medical records at each 
hospital. This study protocol was reviewed and approved by 
the institutional review boards of all participating institu-
tions. Written informed consent was obtained from all pa-
tients. 
Single-cell RNA-seq 
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from peripheral venous blood via standard Ficoll-Paque 
(GE Healthcare, Uppsala, Sweden) density gradient centrifu-
gation, frozen in freezing media, and stored in liquid nitrogen 
until use. All samples showed a high viability of about 90% 
on average after thawing. Single-cell RNA-seq libraries were 
generated using the Chromium Single Cell 3′ Library & Gel 
Bead Kit v3 (10X genomics, Pleasanton, CA) following the 
manufacturer’s instructions. Briefly, thousands of cells were 
separated into nanoliter-scale droplets. In each droplet, 
cDNA was generated through reverse transcription. As a re-
sult, a cell barcoding sequence and Unique Molecular 
Identifier (UMI) were added to each cDNA molecule. Librar-
ies were constructed and sequenced as a depth of approxi-
mately 50,000 reads per cell using the Nextseq 550 or 
Novaseq 6000 platform (Illumina, San Diego, CA). 
Single-cell RNA-seq data processing 
The sequenced data were de-multiplexed using mkfastq 
(cellranger 10X genomics, v3.0.2) to generate fastq files. After 
de-multiplexing, the reads were aligned to the human refer-
ence genome (GRCh38; 10x cellranger reference GRCh38 
v3.0.0), feature-barcode matrices generated using the 
cellranger count, and then aggregated by cellranger aggr us-
ing default parameters. The following analysis was per-
formed using Seurat R package v3.1.5 (17). After generating 
the feature-barcode matrix, we discarded cells that expressed 
<200 genes and genes not expressed in any cells. To exclude 
low-quality cells from our data, we filtered out the cells that 
express mitochondrial genes in >15% of their total gene ex-
pression as described in previous studies (29, 35, 36). Dou-
blets were also excluded, which were dominant in the cluster 
“Uncategorized 1”. Although there was a high variability in 
the number of UMIs detected per cell, majority of cells 
(90.5%) were enriched in a reasonable range of the UMIs 
(1,000 - 25,000), and 59% of cells with less than 1,000 UMIs 
were platelet or RBC excluded in downstream analysis. In 
each cell, the gene expression was normalized based on the 
total read count and log-transformed. To align the cells orig-
inating from different samples, 2000 highly variable genes 
from each sample were identified by the vst method in Seurat 
R package v3.1.5 (17). Using the canonical correlation analysis 
(CCA), we found anchors and aligned the samples based on 
the top 15 canonical correlation vectors. The aligned samples 
were scaled and principal component analysis (PCA) con-
ducted. Finally, the cells were clustered by unsupervised clus-
tering (0.5 resolution) and visualized by tSNE using the top 
15 principal components. 
Cell type annotation through marker gene identification 
in each cluster 
To identify marker genes, up-regulated genes in each clus-
ter relative to the other clusters were selected based on the 
Wilcoxon rank sum test in Seurat’s implementation with 
>0.25 log fold change compared to the other clusters and a 
Bonferroni-adjusted p < 0.05 (Table S4). By manual inspec-
tion, among the 22 different clusters, 20 were assigned to 11 
known immune cell types, RBCs which are characterized by 
HBA1, HBA2, and HBB, and platelets. The clusters character-
ized by similar marker genes were manually combined as one 
cell type. The two remaining clusters were assigned to ‘Un-
categorized 1’ and ‘Uncategorized 2’ because they had no dis-
tinct features of known cell types. Based on the distribution 
of UMI counts, the cluster ‘Uncategorized 1’ was featured by 
relatively high UMIs per cell compared to other clusters and 
presence of higher expression of multiple cell type marker 
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genes. The cluster ‘Uncategorized 2’ was featured by a B cell-
like signatures and high expression of ribosomal protein 
genes, not recommended to be further analyzed according to 
the 10X platform guideline. In these aspects, RBCs, platelets, 
Uncategorized 1, and Uncategorized 2 were excluded in 
downstream analysis. 
Reproducibility of biological replicates 
To check the reproducibility of biological replicates (indi-
viduals within a same group), we calculated the Spearman’s 
rank correlation coefficient for UMI counts that were merged 
according to each individual. The correlation coefficients of 
all individual pairs within the same group were visualized by 
a boxplot (COVID-19, n=45; FLU, n=10; HD, n=6). 
Hierarchical clustering of the transcriptomes at cell 
type resolution 
In Fig. S1E, to investigate the similarity of the transcrip-
tomes between cell types across diseases, we merged the UMI 
counts of each cell type according to healthy donor, influenza, 
mild COVID-19, and severe COVID-19. Next, the UMI counts 
for each gene were divided by the total UMI count in each 
cell type and multiplied by 100,000 as the normalized gene 
expression. Based on a median expression value >0.5, we cal-
culated the relative changes in gene expression divided by the 
median value for each gene. Hierarchical clustering analysis 
was performed based on the PCC of the relative change in 
gene expression. 
Hierarchical clustering of variable gene expression 
among disease groups at cell type resolution 
In Fig. 2A and Fig. S2A, to compare the highly variable 
gene expression among mild and severe COVID-19 and influ-
enza relative to healthy donors, the normalized gene expres-
sion used in Fig. S1E was divided by the values in the healthy 
donor group. We selected the highly variable genes in terms 
of the top 25% standard deviation followed by log2-transfor-
mation (pseudo-count =1). In Fig. 2A, hierarchical clustering 
analysis was performed based on the PCCs of the selected 
highly variable genes. For Fig. S2A, to investigate the expres-
sion patterns of the selected highly variable genes (n=6,052), 
K-means clustering (k=50) was performed based on Euclid-
ean distance. We manually ordered the clusters and visual-
ized them as a heat map, revealing four distinct patterns: 
influenza-specific (n=1,046), COVID-19 specific (n=1,215), in-
fluenza/COVID-19 common (n=1,483), and cell type-specific 
(n=2,308). 
Analysis of dynamic changes in cell type composition 
compared to healthy donors 
To investigate the dynamic changes in cell type composi-
tion, we calculated the proportion of cell types in each indi-
vidual. As a control, we calculated the relative variation in 
each cell type composition between all pairs of healthy do-
nors. Similarly, for each disease group, we calculated the rel-
ative variation in each cell type by dividing the fraction of the 
cell type in individual patient by that of individual healthy 
donor. After log2-transformation, we conducted statistical 
analysis using the relative variation in composition between 
the control and disease groups using a two-sided Kolmogo-
rov–Smirnov test. 
Identification of DEGs using MAST 
For any two transcriptome profiles, to identify DEGs, we 
utilized the model-based analysis of single cell transcriptom-
ics (MAST) algorithm in Seurat’s implementation based on a 
Bonferroni-adjusted p<0.05 and a log2 fold change > 0.25. 
Gene Ontology analysis for biological pathways 
In Fig. 2B, the DEGs in COVID-19 and influenza compared 
to healthy donors or COVID-19 compared to influenza were 
identified at cell type resolution. All DEGs were combined ac-
cording to the disease groups for further analysis. The over-
lapping up or down DEGs between COVID-19 and influenza 
compared to healthy donors were defined as ‘Common up’ or 
‘Common down’. The specific DEGs in COVID-19 or influenza 
were assigned as ‘COVID-19 up/down’ or ‘FLU up/down’, re-
spectively. In addition, COVID-19-specific up- or down-regu-
lated genes compared to influenza were assigned as ‘COVID-
19>FLU’ or ‘FLU>COVID-19’, respectively. The Gene Ontology 
analysis was performed by DAVID. For each group of DEGs, 
the top 10 enriched GO biological pathways were selected, re-
sulting in 49 unique GO biological pathways across all 
groups. The -log10(p-values) are shown as a heat map in Fig. 
2B. 
WGCNA analysis to identify modular gene expression 
patterns 
The weighted gene correlation network analysis 
(WGCNA) was conducted with the genes listed in the top 10 
GO biological pathways of ‘COVID-19 up’, ‘FLU up’, and ‘Com-
mon up’ defined in Fig. 2B. The normalized gene expression 
values of the genes in COVID-19 were divided by the values 
in influenza and log2-transformed (pseudo-count =1). We 
used default parameters with the exception of soft threshold 
=10 and networkType = ‘signed’ when we constructed a top-
ological overlap matrix. The modular gene expression pat-
terns were defined using cutreeDynamic with a 
minClusterSize of 5. We visualized the modular gene expres-
sion pattern as a heat map in which the cell types were or-
dered according to hierarchical clustering with the default 
parameters of hcluster in R. 
Subclustering analysis 
To find disease-specific subpopulations, each immune cell 
type was subjected to the subclustering analysis using Seurat. 
Briefly, the highly variable genes (n=1000) were selected 
based on vst and then scaled by ScaleData in Seurat with the 
vars.to.regress option to eliminate variation between individ-
uals. The subpopulations were identified by FindClusters 
with default parameters, except resolution (non-EM-like 
CD8+ T cells, 0.3; classical monocytes, 0.2); the inputs were 
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the top eight principal components (PCs) obtained from PCA 
of the scaled expression of the highly variable genes. The sub-
populations were visualized by tSNE using the top eight PCs. 
Trajectory analysis 
The trajectory analysis was performed with 2000 highly 
variable genes in classical monocytes across mild (C7-2) and 
severe (C7-1) COVID-19 as defined by the vst method in Seu-
rat. The following analysis was performed using Monocle2. 
Briefly, the input was created from the UMI count matrix of 
the highly variable genes using the newCellDataSet function 
with default parameters, except expressionFamily = ‘negbino-
mial.size’. The size factors and dispersion of gene expression 
were estimated. The dimension of the normalized data was 
reduced based on DDRTree using reduceDimension with de-
fault parameters, except scaling = FALSE, which aligned the 
cells to the trajectory with three distinct clusters. 
To determine genes that gradually changed along the tra-
jectory, we identified the DEGs using MAST between clusters 
1 and 3, which represent the severe stage and mild stage, re-
spectively. The expression patterns of representative DEGs 
were visualized along the Pseudotime after correction with 
estimated size factors and dispersion for all genes. 
K-means clustering analysis of monocytes 
In Fig. 4B, we performed K-means clustering of DEGs 
among all pairs of mild COVID-19, severe COVID-19, and in-
fluenza. The log2-transformed relative gene expression of 
DEGs compared to healthy donors was subjected to K-means 
clustering (k=10). Here, we used up-regulated DEGs in at 
least one disease group compared to the healthy donor group. 
We manually assigned five clusters based on gene expression 
patterns. 
Data analysis of the transcriptome profiles of post-mor-
tem lung tissues 
The transcriptome profiles of post-mortem lung tissues 
from two lethal cases of COVID-19 and biopsied heathy lung 
tissues from two donors were downloaded from a public da-
tabase (GSE147507). The DEGs were identified using DESeq2 
based on a Bonferroni-adjusted p < 0.05 and a log2 fold 
change > 1. 
Enrichment analysis using Enrichr and GSEA 4.0.3 
Enrichr, the web-based software for gene set enrichment 
analysis (GSEA) was used for LINCS L1000 ligand perturba-
tion analysis (22), virus perturbation analysis, and disease 
perturbation analysis from the GEO database. ‘Combined 
score’ was calculated as a parameter of enrichment as the 
log(p-value) multiplied by the z-score from the Fisher exact 
test. GSEA 4.0.3 software was used to conduct the GSEA 
when a ranked list of genes was available (Fig. 5G, Fig. 6C-E) 
(37). Results for IFN-γ-responsive genes were not presented 
because those were considerably overlapped with IFN-α-
responsive genes, which are typical ISGs. The normalized en-
richment score and FDR-q value were calculated to present 
the degree and significance of enrichment. 
Flow cytometry analysis 
Cryopreserved PBMCs were thawed, and dead cells were 
stained using the Live/Dead Fixable Cell Stain kit (Invitrogen, 
Carlsbad, CA). Cells were stained with fluorochrome-conju-
gated antibodies, including anti-CD3 (BV605; BD Biosci-
ences), anti-CD4 (BV510; BD Biosciences), anti-CD8 (BV421; 
BD Biosciences), anti-CD14 (PE-Cy7; BD Biosciences), anti-
CD19 (Alexa Fluor 700; BD Biosciences), and anti-CD56 (Vio-
Bright FITC; Miltenyi Biotec). For staining with anti-
granzyme B (BD Biosciences), cells were permeabilized using 
a Foxp3 staining buffer kit (eBioscience). 
For intracellular cytokine staining of IFN-γ, PBMCs were 
stimulated with phorbol 12-myristate 13-acetate (PMA, 50 
ng/ml) (Sigma Aldrich) and ionomycin (1 μg/ml) (Sigma Al-
drich). Brefeldin A (GolgiPlug, BD Biosciences) and monesin 
(GolgiStop, BD Biosciences) were added 1 hour later. After 
another 5 hours of incubation, cells were harvested for stain-
ing with the Live/Dead Fixable Cell Stain kit, anti-CD3, anti-
CD4, and anti-CD8. Following cell permeabilization, cells 
were further stained with anti-IFN-γ (Alexa Fluor 488; eBio-
science). 
Flow cytometry was performed on an LSR II instrument 
using FACSDiva software (BD Biosciences) and the data ana-
lyzed using FlowJo software (Treestar, San Carlos, CA). 
ELISA and cytometric bead arrays 
Cytokines were measured in plasma samples, including 
IFN-β, IL-18 (ELISA, R&D Systems, Minneapolis, MN), IL-1β 
(Cytometric bead array flex kit, BD Biosciences, San Jose, CA), 
TNF, IL-6, and IFN-γ (LEGENDplex bead-based immunoas-
say kit, BioLegend, San Diego, CA). 
Statistical analysis 
We performed the KS test to compare the distributions of 
two groups without assuming that the distributions follow 
normality. Welch’s t test was conducted to compare the two 
distributions after confirming the normality of the distribu-
tions using the Shapiro-Wilk normality test. A Wilcoxon 
signed rank test was conducted to compare the differences 
between two groups with paired subjects. The Mann-Whitney 
test was performed to compare the means of two groups. Sta-
tistical analyses were performed using Prism software ver-





Fig. S1. Clinical characteristics and assessment of the quality of scRNA-seq results. 
Fig. S2. Transcriptome features of highly variable genes. 
Fig. S3. Characterization of disease-specific CD8+ T-cell subpopulations. 
Fig. S4. Subpopulation analysis of classical monocytes. 
Fig. S5. STRING analysis of up-regulated genes in cluster 1 obtained from the trajec-
tory analysis of classical monocytes. 
Table S1. Experimental batches of scRNA-seq. 
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Fig. 1. Single cell transcriptomes of PBMCs from COVID-19 and influenza patients. (A) tSNE projections of 59,572 
PBMCs from healthy donors (HDs) (4 samples, 17,590 cells), severe influenza (FLU) patients (5 samples, 10,519 cells), 
COVID-19 patients (asymptomatic: 1 sample, 4,425 cells; mild COVID-19: 4 samples, 16,742 cells; severe COVID-19: 6 
samples, 10,296 cells) colored by group information. (B) Normalized expression of known marker genes on a tSNE plot. 
(C) tSNE plot colored by annotated cell types. EM: effector memory, NK cell: natural killer cell, DC: dendritic cell, RBC: red 
blood cell. (D) Proportion of cell types in each group excluding ‘Uncategorized 1’, ‘Uncategorized 2’, ‘RBC’, and ‘Platelet’. 
The colors indicate cell type information. (E) Boxplots showing the fold enrichment in cell type proportions from mild 
COVID-19 (n=4), severe COVID-19 (n=6), and FLU (n=5) patients compared to the HD group (mild COVID-19 vs. HD: n=16, 
severe COVID-19 vs. HD: n=24, FLU vs. HD: n=20). For the boxplots, the box represents the interquartile range (IQR) and 
the whiskers correspond to the highest and lowest points within 1.5 × IQR. ‘Uncategorized 1’ (relatively high UMIs per cells 
and presence of multiple marker genes), ‘Uncategorized 2’ (B cell-like and high expression of ribosomal protein genes), 
‘RBC’, and ‘Platelet’ were excluded. Two-sided Kolmogorov–Smirnov (KS) tests were conducted for each cell type 
between the disease and HD group. *p<0.05, **p<0.01, and ***p<0.001. 
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Fig. 2. Immune 
landscape of COVID-
19. (A) Hierarchical 
clustering using the 
Pearson correlation 
coefficient (PCC) of a 
normalized 
transcriptome 
between diseases in 
cell type resolution (n 
= 33). The color 
intensity of the heat 
map indicates the PCC 
values. The color bars 
above the heat map 
indicate the cell type 
and disease group. 
The black box 
indicates the cell types 
that highly correlate 
between the severe 
COVID-19 and FLU 
groups. (B) Illustration 
of the enrichment p-
values for the select 
GO biological 
pathways (n = 49) of 
differentially 
expressed genes 
(DEGs) in COVID-19 
and FLU patients (left 
6 columns: DEGs for 
COVID-19 and FLU 
groups compared to 
HD, right 2 columns: 
DEGs between COVID-
19 and FLU groups). 
(C) tSNE plot of 
representative gene 
expression patterns 
for GBP1 (FLU 
specific), CREM 
(COVID-19 specific) , 
and CCL3 (COVID-
19/FLU common). (D) 
Top, dendrogram from 
WGCNA analysis 
performed using  
relative normalized gene expression between the COVID-19 and FLU groups for the genes belonging to the select 
biological pathways in (B) (n=316). Bottom, heat map of relative normalized gene expression between the COVID-19 
and FLU groups. The color bar (left) indicates cell type information clustered by hierarchical clustering based on the 
PCC for relative normalized gene expression. Modularized gene expression patterns by WGCNA are shown together 
(G1, n=10; G2, n=147; G3, n=27; G4, n=17; G5, n=12; G6, n=64; G7, n=34; G8, n=5). 




Fig. 3. Subpopulation analysis of CD8+ T cells. (A) tSNE plot of the non-EM-like CD8+ T cell subpopulations 
in all groups (left, n=6,253), COVID-19 (top right, n=2,653), FLU (middle right, n=1,452), and HD (bottom 
right, n=2,148) colored by cluster information. (B, C) Boxplots showing the proportion of individual sub-
clusters from the non-EM-like CD8+ T cell cluster within each group (COVID-19, n=10; FLU, n=5; HD, n=4). 
The proportions follow normal distribution as tested by the Shapiro-Wilk normality test except the proportion 
of cluster 3 in the COVID-19 group (p=0.04). Cluster 1 and cluster 3 were highly enriched in the FLU and 
COVID-19 group, respectively. Two-sided Welch’s t test p-values were 4.4E-03 between COVID-19 and FLU 
in cluster 1, 3.5E-02 between FLU and HD donor in cluster 1, 8.6E-03 between COVID-19 and FLU in cluster 3, 
and 5.8E-3 between COVID-19 and HD in cluster 3. *p<0.05, **p<0.01. (D) STRING analysis using the top 30 
up-regulated genes in cluster 1 (left) and cluster 3 (right). (E) Bar plots showing enrichment p-values of eight 
representative GO biological pathways for pro-inflammation and interferon in cluster 1 or cluster 3-specific 
up-regulated genes (cluster 1, n=66; cluster 3, n=183). 
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Fig. 4. Transcriptome of classical monocytes in COVID-19 patients. (A) Venn diagram of differentially expressed 
genes (DEGs) in COVID-19 and FLU compared to HD. The representative genes are shown together. (B) K-means 
clustering of DEGs between all pairs of FLU, mild COVID-19, and severe COVID-19 (n=499). The color indicates the 
relative gene expression between the diseases and HD. The representative genes are shown together. (C) Bar plots 
showing the average –log10(p-value) values in enrichment analysis using the perturbed genes of four different cell 
lines listed in L1000 LINCS for up-regulated genes in cluster 2 (C2, left) and cluster 3 (C3, right). Error bars indicate 
standard deviation. (D) Combined enrichment scores were compared between C2 and C3 for the gene sets of the type 
I IFN response (left; GSE26104) and TNF response (right; GSE2638, GSE2639). **p<0.01. Each dot indicates an 
individual subject. (E) Bar plots showing the average –log10(p-value) values in the enrichment analysis using the 
perturbed genes listed of four different cell lines in L1000 LINCS for up-regulated genes in cluster 4 (C4, left) and 
cluster 5 (C5, right). Error bars indicate standard deviation (C and E). 
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Fig. 5. Trajectory 
analysis of classical 
monocytes. (A) Vol-
cano plot showing 
DEGs between mild 
and severe COVID-19 
groups. Each dot indi-
cates individual gene, 
colored by red when a 
gene is significant 
DEG. (B) Bar plot 
showing the average –
log10(p-value) values 
in enrichment analysis 
using the perturbed 
genes of four different 
cell lines listed in 
L1000 LINCS for up-
regulated genes in the 
severe COVID-19 
group. Error bars indi-
cate standard devia-
tion. (C) Trajectory 
analysis of classical 
monocytes from speci-
mens obtained at two 
different time points in 
a single COVID-19 pa-
tient (mild: C7-2, 1,197 
cells; severe: C7-1, 631 
cells). The color indi-
cates cluster infor-
mation (left) or the 
severity of COVID-19 
(right). (D) Relative ex-
pression patterns of 
representative genes 
in the trajectory analy-
sis are plotted along 
the Pseudotime. The 
color indicates the rel-
ative gene expression 
calculated by Monocle 
2. (E) Bar plots show-
ing the average –
log10(p-value) values 
in the enrichment anal-
ysis using the per-
turbed genes of four 
different cell lines in 
L1000 LINCS for up- 
regulated genes in cluster 3 (left) and cluster 1 (right). Error bars indicate standard deviation. (F) Comparison of 
combined enrichment scores between cluster 3 and cluster 1 for the gene sets from systemic lupus erythema tosus 
(SLE) (n=16) and rheumatoid arthritis (RA) (n=5). ***p<0.001; ns, not significant. (G) GSEA of up-regulated genes in 
cluster 3 (left) and cluster 1 (right) to the ‘class 1’ gene module of monocyte-derived macrophages by Park et al. (2017). 
NES: normalized enrichment score, FDR: false discovery rate. 







Fig. 6. Validation of the combined IFN-I and inflammatory responses in the transcriptome of post-mortem 
lung tissues from lethal COVID-19. (A) UCSC Genome Browser snapshots of representative genes. (B) Bar plot 
showing the average –log10(p-value) values from the enrichment analysis using the perturbed genes of four 
different cell lines in L1000 LINCS for up-regulated genes (n= 386) in post-mortem lung tissues compared to 
biopsied healthy lung tissue. Error bars indicate standard deviation. (C) GSEA of significantly up- and down-
regulated genes in post-mortem lung tissues for gene sets originated from up-regulated genes in C2 (n=96), C3 
(n=143), C4 (n=218), and C5 (n=30) of Fig. 4B. (D and E) GSEA of significantly up- and down-regulated genes in 
post-mortem lung tissues for gene sets originated from the top 200 up-regulated genes in cluster 3 (left) and 
cluster 1 (right) from the trajectory analysis in Fig. 5C (D), and from gene sets originated from the top 200 up-
regulated genes in classical monocytes of mild (left) and severe (right) COVID-19 (E). 
